J. Barbet, L. Campion, F. Kraeber-bodéré, and J. F. Chatal, Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma, J. Clin. Endocrinol. Metab, vol.90, pp.6077-6084, 2005.

J. Barbet, P. Peltier, S. Bardet, J. P. Vuillez, I. Bachelot et al., Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody, J. Nucl. Med, vol.39, pp.1172-1178, 1998.

O. C. Boerman, M. H. Kranenborg, E. Oosterwijk, G. L. Griffiths, W. J. Mcbride et al., Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate, Cancer Res, vol.59, pp.4400-4405, 1999.

E. S. Bos, W. H. Kuijpers, M. Meesters-winters, D. T. Pham, A. S. De-haan et al., In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer, Cancer Res, vol.54, pp.3479-3486, 1994.

C. H. Chang, R. M. Sharkey, E. A. Rossi, H. Karacay, W. Mcbride et al., Molecular advances in pretargeting radioimunotherapy with bispecific antibodies, Mol. Cancer Ther, vol.1, pp.553-563, 2002.

J. F. Chatal, L. Campion, F. Kraeber-bodéré, S. Bardet, J. P. Vuillez et al., French Endocrine Tumor Group. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anticarcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group, J. Clin. Oncol, vol.24, pp.1705-1711, 2006.

D. Delbeke, Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma, J. Nucl. Med, vol.40, pp.591-603, 1999.

E. Frampas, C. Maurel, . Remaud-le, P. Saëc, T. Mauxion et al., Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide, Eur. J. Nucl. Med. Mol. Imaging, vol.38, pp.2153-2164, 2011.

E. Gautherot, J. M. Le-doussal, J. Bouhou, C. Manetti, M. Martin et al., Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens, J. Nucl. Med, vol.39, pp.1937-1943, 1998.

E. Gautherot, E. Rouvier, L. Daniel, E. Loucif, J. Bouhou et al., Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131 I-labeled bivalent hapten, J. Nucl. Med, vol.41, pp.480-487, 2000.

J. F. Gestin, A. Loussouarn, M. Bardiès, E. Gautherot, A. Gruaz-guyon et al., Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188 Re-labeled bivalent hapten: biodistribution and dosimetry studies, J. Nucl. Med, vol.42, pp.146-153, 2001.

D. M. Goldenberg, Perspectives on oncologic imaging with radiolabeled antibodies, Cancer, vol.80, pp.2431-2435, 1997.

D. M. Goldenberg, C. H. Chang, R. M. Sharkey, E. A. Rossi, H. Karacay et al., Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?, Eur. J. Nucl. Med. Mol. Imaging, vol.30, pp.777-780, 2003.

D. M. Goldenberg, D. F. Preston, F. J. Primus, and H. J. Hansen, Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G, Cancer Res, vol.34, pp.1-9, 1974.

D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J. F. Chatal, Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy, J. Clin. Oncol, vol.24, pp.823-834, 2006.

D. A. Goodwin, C. F. Meares, M. J. Mccall, M. Mctigue, and W. Chaovapong, Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens, J. Nucl. Med, vol.29, pp.226-234, 1988.

D. A. Goodwin, C. F. Meares, M. Mctigue, W. Chaovapong, C. I. Diamanti et al., Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake, J. Nucl. Med, vol.33, pp.2006-2013, 1992.

D. A. Goodwin, C. F. Meares, N. Watanabe, M. Mctigue, W. Chaovapong et al., Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in, BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy, Cancer Res, vol.54, pp.5937-5946, 1994.

S. V. Govindan and D. M. Goldenberg, New antibody conjugates in cancer therapy, ScientificWorldJournal, vol.10, pp.2070-2089, 2010.

M. Jain, G. Venkatraman, and S. K. Batra, Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation, Clin. Cancer Res, vol.13, pp.1374-1382, 2007.

E. Janevik-ivanovska, E. Gautherot, M. Hillairet-de-boisferon, M. Cohen, G. Milhaud et al., Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy, Bioconjug. Chem, vol.8, pp.526-533, 1997.

H. Karacay, R. M. Sharkey, D. V. Gold, D. R. Ragland, W. J. Mcbride et al., Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90 Y-IMP-288 alone and combined with gemcitabine, J. Nucl. Med, vol.50, 2008.

G. Kohler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.256, pp.495-497, 1975.

F. Kraeber-bodéré, S. Bardet, C. A. Hoefnagel, M. R. Vieira, J. P. Vuillez et al., Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial, Clin Cancer Res, vol.5, pp.3190-3198, 1999.

F. Kraeber-bodéré, A. Faibre-chauvet, C. Saï-maurel, E. Gautherot, M. Fiche et al., Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft, J. Nucl. Med, vol.40, pp.198-204, 1999.

F. Kraeber-bodéré, A. Faivre-chauvet, L. Ferrer, J. P. Vuillez, P. Y. Brard et al., Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x antihapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial, Clin Cancer Res, vol.9, pp.3973-3981, 2003.

F. Kraeber-bodéré, C. Rousseau, C. Bodet-milin, L. Ferrer, A. Faivre-chauvet et al., Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial, J. Nucl. Med, vol.47, pp.247-255, 2006.

M. H. Kranenborg, O. C. Boerman, J. C. Oosterwijk-wakka, M. C. De-weijert, F. H. Corstens et al., Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies, Int. J. Cancer, vol.75, pp.74-80, 1998.

L. Doussal, J. M. Chetanneau, A. Gruaz-guyon, A. Martin, M. Gautherot et al., Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response, J. Nucl. Med, vol.34, pp.1662-1671, 1993.

L. Doussal, J. M. Gruaz-guyon, A. Martin, M. Gautherot, E. Delaage et al., Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice, Cancer Res, vol.50, p.6115, 1990.

L. Doussal, J. M. Martin, M. Gautherot, E. Delaage, M. Barbet et al., In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate, J. Nucl. Med, vol.30, pp.1358-1366, 1989.

C. Lollo, S. Halpern, R. Bartholomew, G. David, and P. Hagan, Noncovalent antibody-mediated drug delivery, Nucl. Med. Commun, vol.15, pp.483-491, 1994.

D. G. Maloney, A. J. Grillo-lopez, C. A. White, D. Bodkin, R. J. Schilder et al., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood, vol.90, pp.2188-2195, 1997.

W. J. Mcbride, R. M. Sharkey, H. Karacay, C. A. Souza, E. A. Rossi et al., A novel method of 18 F radiolabeling for PET, J. Nucl. Med, vol.50, pp.991-998, 2009.

W. J. Mcbride, P. Zanzonico, R. M. Sharkey, C. Norén, H. Karacay et al., Bispecific antibody pretargeting PET (immunoPET) with an 124 I-labeled hapten-peptide, J. Nucl. Med, vol.47, pp.1678-1688, 2006.

E. Mirallié, J. P. Vuillez, S. Bardet, E. Frampas, B. Dupas et al., High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer, J. Clin. Endocrinol. Metab, vol.90, pp.779-788, 2005.

G. Paganelli and M. Chinol, Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?, Eur. J. Nucl. Med. Mol. Imaging, vol.30, pp.773-776, 2003.

G. Paganelli, P. Magnani, F. Zito, E. Villa, F. Sudati et al., Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients, Cancer Res, vol.51, pp.5960-5966, 1991.

P. Peltier, C. Curtet, J. F. Chatal, J. M. Le-doussal, G. Daniel et al., Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer, J. Nucl. Med, vol.34, pp.1267-1273, 1993.

E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, W. J. Mcbride, R. M. Sharkey et al., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, 2006.

, Proc. Natl. Acad. Sci. U.S.A, vol.103, pp.6841-6846

P. Y. Salaun, L. Campion, C. Ansquer, E. Frampas, C. Mathieu et al., 18 F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma, Eur. J. Nucl. Med. Mol. Imaging, vol.41, pp.1501-1510, 2014.

P. Y. Salaun, L. Campion, C. Bournaud, A. Faivre-chauvet, J. P. Vuillez et al., Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement, J. Nucl. Med, vol.53, pp.1185-1192, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00932253

R. Schoffelen, O. C. Boerman, D. M. Goldenberg, R. M. Sharkey, C. M. Van-herpen et al., Development of an imaging-guided CEApretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, Br. J. Cancer, vol.109, pp.934-942, 2013.

R. Schoffelen, R. M. Sharkey, D. M. Goldenberg, G. Franssen, W. J. Mcbride et al., Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68 Ga-and 18 F-labeled hapten peptide in mice with human tumor xenografts, Mol. Cancer Ther, vol.9, pp.1019-1027, 2010.

R. Schoffelen, W. T. Van-der-graaf, G. Franssen, R. M. Sharkey, D. M. Goldenberg et al., Pretargeted 177 Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice, J. Nucl. Med, vol.51, pp.1780-1787, 2010.

R. Schoffelen, W. Woliner-van-der-weg, E. P. Visser, D. M. Goldenberg, R. M. Sharkey et al., Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, Eur. J. Nucl. Med. Mol. Imaging, vol.41, pp.1593-1602, 2014.

R. Schoffelen, W. T. Van-der-graaf, R. M. Sharkey, G. M. Franssen, W. J. Mcbride et al., Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer, J. Nucl. Med, vol.53, pp.1926-1932, 2012.

J. Schuhmacher, S. Kaul, G. Klivényi, H. Junkermann, A. Magener et al., Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies, Cancer Res, vol.61, pp.3712-3717, 2001.

R. M. Sharkey, W. J. Mcbride, H. Karacay, K. Chang, G. L. Griffiths et al., A universal pretargeting system for cancer detection and therapy using bispecific antibody, Cancer Res, vol.63, pp.354-363, 2003.

R. M. Sharkey, C. M. Van-rij, H. Karacay, E. A. Rossi, C. Frielink et al., A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers, J. Nucl. Med, vol.53, pp.1625-1632, 2012.

D. R. Stickney, L. D. Anderson, J. B. Slater, C. N. Ahlem, G. A. Kirk et al., Bifunctional antibody: a binary radio-pharmaceutical delivery system for imaging colo-rectal carcinoma, Cancer Res, vol.51, pp.6650-6655, 1991.

G. A. Van-dongen and M. J. Vosjan, Immuno-positron emission tomography: shedding light on clinical antibody therapy, Cancer Biother. Radiopharm, vol.25, pp.375-385, 2010.

C. M. Van-rij, S. Lütje, C. Frielink, R. M. Sharkey, D. M. Goldenberg et al., Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody, Eur. J. Nucl. Med. Mol. Imaging, vol.40, pp.1377-1383, 2013.

D. J. Vugts, G. W. Visser, and G. A. Van-dongen, 89 Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals, Curr. Top. Med. Chem, vol.13, pp.446-457, 2013.

J. P. Vuillez, D. Moro, P. Y. Brichon, E. Rouvier, E. Brambilla et al., Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer, J. Nucl. Med, vol.38, pp.507-511, 1997.

R. B. Wilder, G. L. Denardo, and S. J. Denardo, Radioimmunotherapy: recent results and future directions, J. Clin. Oncol, vol.14, pp.1383-1400, 1996.

, Conflict of Interest Statement: Dr. Sharkey is an employee of Immunomedics, Inc. Dr. Goldenberg is stockholder and officer of Immunomedics

©. Copyright, . Kraeber-bodéré, . Rousseau, . Bodet-milin, . Frampas et al., This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, 2015.